Sept. 25, 2017:
The Big Ten Cancer Research Consortium (Big Ten CRC) announces the opening of a clinical trial for patients with advanced or recurrent endometrial cancer.
The study, known as BTCRC-GYN15-013, involves pembrolizumab, one of a new class of drugs called PD-1 inhibitors, given in combination with routine care using paclitaxel and carboplatin chemotherapy. [Pictured: Study sponsor-investigator Daniela Matei, MD of Northwestern University Feinberg School of Medicine.]
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago is currently enrolling subjects in this study. Additional member sites within the Big Ten Cancer Research Consortium will open the trial in the coming months. Read More
Subscribe to the Big Ten CRC NewsletterXFacebookYouTube